Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, October 23, 2026

Back to today

From X

@convequity

Convequity on X

Neoclouds Now Trade as a Hedge Against AI Demand Growth Convequity’s latest ABBX review shows $CRWV, $NBIS and $IREN are inversely correlated with AI demand growth. Stronger demand widens the working-capital hole and keeps investors risk-off, even as order books expand. Insatiable demand is usually the reason to own the supplier. Here it does the opposite. Jensen Huang told CNBC at GTC Berlin that neocloud demand is “off the charts” and that working capital is the missing piece. Working capital is current assets minus current liabilities. A cash-conversion mismatch squeezes it even when demand is huge. Liabilities hit first. A neocloud pays $NVDA and networking suppliers in roughly 30–60 days. Asset-backed hardware loans add heavy near-term debt service. Assets lag. A signed customer contract sits off the balance sheet as backlog. It only becomes receivables or cash once the cluster is deployed, energized and billed — months later. Cash leaves before revenue arrives. A faster pipeline simply widens the short-term deficit. Latest ABBX figures NBIS: $8.5B gross debt vs $8.0B cash; guidance for >$9B customer prepayments this year. IREN: $7.6B debt vs $5.9B cash; $13.8B hardware and site commitments; 20% prepay on the Microsoft contract. CRWV: $35.6B debt vs $5.5B cash, plus $16.3B operating leases and $35.5B rent not yet commenced. Build-out relies far more on debt than customer prepayments. Even with those prepayments, NBIS and IREN keep raising large extra funding. CRWV faces the same hole with a far larger debt stock. Handing contracts back to resell at higher spot prices would ease CRWV’s cash hole only if customers and lenders agreed. Customers pay even if they do not use the capacity, CRWV must deliver it, and we found no public right to change the price or exit early. Break a customer contract and the hardware lenders can lock up CRWV’s cash. If that lockup holds, they take the cash to repay the loan. Borrowing later would cost more, and the switch only pays while spot stays high. If spot fell, CRWV would lose both the committed revenue and the contract value backing those loans. For investors to turn risk-on again, AI demand growth needs to slow enough for infrastructure supply to catch up.
@BrokenMoats 1 click

Broken Moats on X

Gaslighting how $RNG talks about cash flow but ignore the 240m in SBC (roughly 40% of that number). Talking 22-23x cash flow at the implied open. 85x roughly gap eps numbers....for a business that has inflected from 5.5 to 6% growth this year.....They can talk AI and % of ARR abut at the end of it the total impact is having a marginal move on the business. They did some nice work to clean up some costs and get profitability to true gap levels. But that was from bloated application days and low hanging fruit. Thats the move from 14-40. Very difficult for this math of fundamentally make sense from hereat these levels.
@aleabitoreddit

Serenity on X

Pretty crazy Reuters piece on the global selloff. - October 22 marked the 1st time since the COVID crash that long/short, systematic, and multi-strategy hedge funds tracked by Goldman Sachs ALL lost more than 1% in a single day. - Tech-focused hedge funds: down ~10% in October - Asia-focused hedge funds: down ~9% in October There’s separate interviews where Citadel/JP Morgan have been saying retail has been the ones buying the dip in semiconductor, neocloud, and memory stocks. And the stocks bought by most retail were $NBIS, $SNDK, and $TSM. Reuters stated this downturn triggered institutional deleveraging events among hedge funds. Quite the divergence, I do think there’s been a ton of irrational selling now, hedge fund deleveraging seems to be a major contributor.

Investor Letters

All letters

Capital Wars

CoreWeave’s $35 billion to $39 billion 2026 spending plan relies on debt as unsecured yields reach 15%, making its GPU cloud expansion a…

CRWV $34B
Net Interest 6 clicks

Putting bear cases to rest

Medpace authorized $1 billion of buybacks through 2028 after Q3 revenue rose 8.5% to $716 million; service revenue grew roughly 12% as…

MEDP $18B
Best Anchor Stocks 9 clicks
PYPD · long

Polypid LTD

PolyPid, an $80 million Israeli biotech, fell nearly 30% despite solving a clinical problem.

PYPD $103M
Value Investors Club

MYR Group q3’26 Earnings Preview

MYR Group’s Q3 2026 preview cites data-center and power transmission demand, with long-term service agreements supporting margin growth and…

MYRG $4B
Monte Independent Investment Research 5 clicks

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 26 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 4 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $108M
Triple S Special Situations Investing 4 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 55 of 247

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.